Current Treatment Options in Neurology

, Volume 14, Issue 2, pp 137–149

Therapeutics in Huntington’s Disease

Cognitive Disorders (M Geschwind, Section Editor)

Opinion statement

There is no specific treatment for Huntington’s disease (HD). Its many symptoms of motor, psychiatric, and cognitive deterioration are managed with symptomatic relief, rehabilitation, and support. The only drug approved by the US Food and Drug Administration (FDA) for the treatment of HD is an antichoreic agent, tetrabenazine, but this drug is used sparingly because of uneasiness regarding its propensity to cause depression and suicidality in this population, which is already at risk for these complications. Neuroleptics are still first-line treatments for chorea accompanied by comorbid depression and/or behavioral or psychotic symptoms, as is often the case. Psychiatric features, which have a significant impact on a patient’s professional and personal life, often become the major focus of management. In addition to neuroleptics, commonly used medications include antidepressants, mood stabilizers, anxiolytics, and psychostimulants. In contrast, few treatment options are available for cognitive impairment in HD; this remains an important and largely unmet therapeutic need. HD patients typically lack insight into their disease manifestations, failing to recognize their need for treatment, and possibly even arguing against it. Multipurpose medications are employed advantageously to simplify the medication regimen, so as to facilitate compliance and not overwhelm the patient. For example, haloperidol can be prescribed for a patient with chorea, agitation, and anorexia, rather than targeting each symptom with a different drug. This approach also limits the potential for adverse effects, which can be difficult to distinguish from the features of the disease itself. With HD’s complexity, it is best managed with a multidisciplinary approach that includes a movement disorders specialist, a genetic counselor, a mental health professional, a physical therapist, and a social worker for support and coordination of services. As the disease progresses, there may be need for other specialists, such as a speech and occupational therapist, a nutritionist for weight loss, and ultimately, a palliative care specialist.

Keywords

Huntington’s disease Huntington disease Chorea Treatment Therapy Tetrabenazine Neuroleptics Haloperidol Juvenile Huntington’s disease Pharmacologic treatment Trinucleotide repeat disorder 

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Huntington G. On chorea. Med Surg Rep. 1872;26:317–21.Google Scholar
  2. 2.
    The Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell. 1993;72:971–83.CrossRefGoogle Scholar
  3. 3.
    Hodgson JG, Agopyan N, Gutekunst CA, et al. A YAC mouse model for Huntington’s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron. 1999;23:181–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Walker FO. Huntington’s disease. Lancet. 2007;369:218–28.PubMedCrossRefGoogle Scholar
  5. 5.•
    Venuto CS, McGarry A, Ma Q, Kieburtz K. Pharmacologic approaches to the treatment of Huntington’s disease. Mov Disord. 2011 Oct 13 (Epub ahead of print). This is a recent detailed review of the pharmacological aspects of the medications currently used in HD and of those being evaluated for future use.Google Scholar
  6. 6.
    Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008;5:181–97.PubMedCrossRefGoogle Scholar
  7. 7.
    Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington’s disease. Mov Disord. 2008;23:1491–504.PubMedCrossRefGoogle Scholar
  8. 8.•
    Ross CA, Tabrizi SJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83–98.PubMedCrossRefGoogle Scholar
  9. 9.•
    Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006;66:366–72.CrossRefGoogle Scholar
  10. 10.
    Poon LH. Role of tetrabenazine for Huntington’s disease-associated chorea. Ann Pharmacother. 2010;44:1080–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington’s disease: an open label study. Clin Neuropharmacol. 2002;25:263–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Squitieri F, Cannella M, Piorcellini A, et al. Shortterm effects of olanzapine in Huntington’s disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14:69–72.PubMedGoogle Scholar
  13. 13.
    Dallocchio C, Buffa C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol. 1999;19:101–3.PubMedCrossRefGoogle Scholar
  14. 14.
    Duff K, Beglinger LJ, O’Rourke ME, et al. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington’s disease. Ann Clin Psychiatry. 2008;20:1–3.PubMedCrossRefGoogle Scholar
  15. 15.
    Giménez-Roldán S, Mateo D. Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements. Neurologia. 1989;4:282–7.PubMedGoogle Scholar
  16. 16.
    Peiris JB, Boralessa H, Lionel ND. Clonazepam in the treatment of choreiform activity. Med J Aust. 1976;1:225–7.PubMedGoogle Scholar
  17. 17.
    Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington’s disease. Psychosomatics. 2006;47:70–2.PubMedCrossRefGoogle Scholar
  18. 18.
    Saft C, Lauter T, Kraus PH, et al. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington’s Disease patients: a case series. BMC Neurol. 2006;6:11.PubMedCrossRefGoogle Scholar
  19. 19.
    Holl AK, Wilkinson L, Painold A, et al. Combating depression in Huntington’s disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol. 2010;25:46–50.PubMedCrossRefGoogle Scholar
  20. 20.
    Duan W, Peng Q, Masuda N, et al. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington’s disease. Neurobiol Dis. 2008;30:312–22.PubMedCrossRefGoogle Scholar
  21. 21.
    Duan W, Guo Z, Jiang H, et al. Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann Neurol. 2004;55:590–4.PubMedCrossRefGoogle Scholar
  22. 22.
    de Tommaso M, Specchio N, Sciruicchio V, et al. Effects of rivastigmine on motor and cognitive impairment in Huntington’s disease. Mov Disord. 2004;19:1516–8.PubMedCrossRefGoogle Scholar
  23. 23.
    de Tommaso M, Difruscolo O, Sciruicchio V, et al. Two years’ follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol. 2007;30:43–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Cubo E, Shannon KM, Tracy D, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology. 2006;67:1268–71.PubMedCrossRefGoogle Scholar
  25. 25.
    Brown GR. The use of methylphenidate for cognitive decline associated with HIV disease. Int J Psychiatry Med. 1995;25:21–37.PubMedCrossRefGoogle Scholar
  26. 26.
    Brown TE, Landgraf JM. Improvements in executive function correlate with enhanced performance and functioning and health-related quality of life: evidence from 2 large, double-blind, randomized, placebo-controlled trials in ADHD. Postgrad Med. 2010;122:42–51.PubMedCrossRefGoogle Scholar
  27. 27.
    Beglinger LJ, Adams WH, Paulson H, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol. 2009;29:484–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Tan E, Jankovic J, Ondo W. Bruxism in Huntington’s disease. Mov Disord. 2000;15:171–3.PubMedCrossRefGoogle Scholar
  29. 29.
    Burbaud P, Ducerf C, Cugy E, et al. Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. J Neurol. 2011;258:1670–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington’s disease. Parkinsonism Relat Disord. 2007;13:453–4.PubMedCrossRefGoogle Scholar
  31. 31.
    Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology. 2001;57:397–404.Google Scholar
  32. 32.
    Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG. Neurology. 2006;66:250–2.PubMedCrossRefGoogle Scholar
  33. 33.
    de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. on behalf of the MermaiHD study investigators. Pridopidine for the treatment of motor function in patients with Huntington’s disease: a phase 3, randomised, placebo-controlled trial. Lancet Neurol. 2011;10:1049–57.PubMedCrossRefGoogle Scholar
  34. 34.
    Zeef D, Schaper F, Vlamings R, et al. Deep brain stimulation in Huntington’s disease: the current status. Open Neurosurg J. 2011;4:7–10.CrossRefGoogle Scholar
  35. 35.
    Hauser RA, Furtado S, Cimino CR, et al. Bilateral human fetal striatal transplantation in Huntington’s disease. Neurology. 2002;58:687–95.PubMedGoogle Scholar
  36. 36.
    Southwell AL, Patterson PH. Gene therapy in mouse models of Huntington disease. Neuroscientist. 2011;17:153–62.PubMedCrossRefGoogle Scholar
  37. 37.
    Jongen P, Renier W, Gabreels F. Seven cases of Huntington’s disease in childhood and levodopa induced improvement in the hypokinetic—rigid form. Clin Neurol Neurosurg. 1980;82:251–61.PubMedCrossRefGoogle Scholar
  38. 38.
    Striano P, Manganelli F, Boccella P, et al. Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord. 2005;20:1610–4.PubMedCrossRefGoogle Scholar
  39. 39.
    de Tommaso M, Di Fruscolo O, Sciruicchio V, et al. Efficacy of levetiracetam in Huntington disease. Clin Neuropharmacol. 2005;28:280–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Experimental Therapeutics in Movement DisordersUniversity of Rochester School of Medicine and DentistryRochesterUSA
  2. 2.Movement and Inherited Neurological Disorders Unit in the Department of NeurologyUniversity of Rochester School of Medicine and DentistryRochesterUSA

Personalised recommendations